Introduction

I
n Spain, a large number of biobanks that hold human biological samples and associated data for research are grouped together in the Spanish National Biobank Network (ReTBioH), organized under the National Institute of Health Charles III (Instituto de Salud Carlos III). The network aims to coordinate, promote and harmonize the various centers that comprise it, and support the growth of Spanish scientific production in biomedicine. The new Spanish regulatory framework, 1 which stipulates the basic requirements for authorization and operation of biobanks, 2 defines biobanks as non-profit entities. However, it allows for the possibility of developing a fee-per-sample structure as a way to recover the operating and distribution costs incurred when the biobank sends samples out to researchers.
In this context, the actual situation of Spanish biobanks in relation to cost calculation can be summarized as follows:
1. Lack of previous work on calculating costs of tangible assets in the public sector in general, and in the biobank sector, in particular. 2. Limited economic orientation and limited attention to cost analysis by biobank managers. In Spain, prior to the present regulatory framework, these organizations used to offer their products or services at no charge or at a price far below their actual production cost. Hence, in-depth knowledge of costs has not been a high priority for managers. 3. Reduced ability to benefit from existing cost models that are already implemented in hospitals and that primarily value processes, not products. 4. Heterogeneous production processes and a large variety of end-products that hinder the development of a common model for all biobanks. 5. Lack of disaggregated accounting information to facilitate data collection for the cost analysis system.
Cost accounting has evolved very intensely in hospitals in recent years, especially in the field of hospitalization, where the development of systems based on the characteristics and condition of patients (case mix systems) allow for a better knowledge of hospital products. 3, 4 However, even though studies have shown the need to have a welldefined fee-per-service model based on cost information, 5 international scientific literature lacks proposals for cost accounting models specifically directed towards biobanks. 6 From this perspective, available studies have only analyzed the costs of developing and maintaining operations at biobanks. 
Design of the Cost Analysis Model
The methodology applied in analyzing and outlining the production process required the following phases of a cycle of cost analysis to be completed:
1. Determination of the stages of the production process. 2. Determination of the cost objects. 3. Identification and classification of the costs involved in the calculations. 4. Allocation, distribution and attachment of costs to each cost object.
Following is a brief description of each of the four phases.
Determination of the Stages of the Production Process
The production process carried out by biobanks varies depending on the type of sample managed: tumor tissue, DNA, blood, serum, neurological tissues, etc. However, there are certain basic stages that are common to the different production processes, no matter what type of sample is collected. Six common stages were identified, as shown in Figure 1 .
As an example, in a hospital-based solid tissue bank, the first stage (collection in laboratory) could imply attaining informed consent; collecting the biological material after surgery and transporting it to the biobank laboratory; and receiving the biological material along with all of the relevant documentation.
The second stage (processing of the biospecimens) could involve examining and selecting the biological material for the biobanking activity (usually done by a pathologist or other trained medical personnel); freezing the biological material in a cryomold, identifying with a code number and/ or barcode; fixing biological material and subsequently embedding it in paraffin blocks; reviewing and annotating the representativeness and quality of the sample by a pathologist; aliquoting or carrying out other modifications, if necessary; and annotating pre-analytical conditions.
FIG. 1.
Stages of the production process.
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The third stage (storage) would entail storing biological samples in ultra-freezers or at room temperature in archives designed for this purpose; and entering clinical and personal data in the biobank database.
The fourth stage (reception of order) would consist in the reception of order form requesting samples and all information pertaining to the research project. Administrative personnel must review all documentation, request further documents if necessary, and attain further official approvals whenever necessary (scientific committee, bioethics committee, etc.).
Once the application for samples is approved, in the fifth stage (sample processing), the biological material must be retrieved from storage and processed according to the specifications given by the researchers. When clinical data are requested, it must be treated confidentially in accordance to the current legal and ethical framework.
Finally, in the sixth stage (distribution of samples) the samples are shipped to the researchers. When shipping, hazardous or frozen materials must be packaged in accordance to established protocols.
Determination of the Cost Objects
Cost object is defined as any activity for which a separate measurement of cost is desired. This model identifies four cost objects:
1. Stored Product: Includes all costs required to treat the biological material received at the biobank for subsequent storage. This concept contains the first three stages of the production process presented in Figure 1 . It is used to value the biological material in storage. The resulting costs are attached proportionately to the cost of the sample as a function of the average number of samples obtained from each unit of stored product. The average number of samples per unit of product stored will depend on the type of biological material in question (tumor tissue, DNA, etc.). 2. Sample: Comprises all costs involved in processing the samples up to the point where they are ready to be distributed, according to the specifications given by the researchers. It is a cost per unit for each of the samples ordered and corresponds to the fifth stage of the production process (see Fig. 1 ) along with the proportional attachment of the cost per unit of stored product. 3. Reception of order and shipping: This includes all the costs incurred when an order for samples is received and sent out to researchers. It includes costs like the review of the research project paperwork or the packaging in which the samples are sent. This cost can be considered a fixed cost no matter the number of samples required. This cost object encompasses the fourth and sixth stages of the production process (see Fig. 1 ). 4. Order: Finally, the cost per order is the sum of the costs per sample plus reception of order and shipping costs. This provides the total cost of the samples for a given order.
Short example (Costs in dollars are not real, they are provided for the purpose of clarity)
In a blood bank the cost of a unit of stored product is calculated by taking into account all the costs incurred in stages 1 through 3 of the production process: performing a phlebotomy, acquiring the informed consent, processing in the lab to yield 1 unit of buffy coat and 4 units of plasma; and storing said units. If total costs are $35, then each unit of stored product (1 st cost object) will have a cost of $7 (35/5). If a pre-set standard sample size of 1ug of DNA from buffy coat is assumed, a total of 100 ug DNA can be extracted from the buffy coat. If the cost of extracting 100 ug DNA is $50 (stage 5th sample processing) then the cost of each sample (2 nd cost object) of 1ug DNA would be the result of the following calculations:
7/100 = 0.07 (proportionate cost of 1 sample in relation to 1 unit of stored product) 50/100 = 0.50 (proportionate cost of processing buffy coat to extract 1 DNA sample) 0.50 + 0.07 = $0.57 per sample (the sum of both costs) Afterwards, all the administrative costs incurred in reviewing and accepting the order as well as shipping costs (3 rd cost object) must be taken into account, to find the total cost for this specific order (4 th cost object).
Identification and Classification of Costs Involved in the Calculations
In this phase it is necessary to determine the nature of the expenses for each stage from the perspective of the cost accounting tool, i.e., standard costing vs. actual costing, according to the needs. The proposed model can be easily adapted to both systems. Afterwards, all costs are classified into the following categories:
Direct Costs: Include direct materials used in the process, which are basically, consumables and reagents required to perform each of the activities: cryomolds, cassettes, microtube racks, glass, formaldehyde, paraffin, isopentane, haematoxylin-eosin, dry ice, etc. (see Fig. 2 ). Indirect Costs: Refer to personnel costs (include salaries as well as social security or health insurance, taxes or even associated costs such as training or uniforms), depreciation and other costs, such as utilities, rent, maintenance costs or cleaning services. In so far as personnel costs are concerned, it is necessary to calculate which part of the cost is devoted exclusively to activity within the biobank; workers in the biobank in some cases may have other responsibilities. This is usually the case in hospital-based biobanks (see Fig. 2 ).
FIG. 2. Direct and indirect costs.
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On the other hand, opportunity costs only apply to the use of scarce resources and they do not involve cash outlays. Thus, they are not usually recorded in the accounting systems. This is why they were not explicitly considered in this proposed model. However, it is noteworthy to point out that these kinds of costs are critically important for decisionmaking. Thus, managers should include them whenever they are deemed appropriate. 8 Allocation, Distribution, and Attachment of Costs to Each Cost Object Figure 3 schematically shows the process of allocation, distribution and attachment of costs for each cost object. Therefore, each cost component identified above must first be allocated to the different stages of the production process in which they are consumed. Direct costs are allocated directly and indirect costs are allocated using an overhead rate. That is, to allocate indirect costs the consumption of each one of the cost elements (for example, cleaning or electricity) must be considered (time in the case of personnel, or Kw/ hour in the case of electricity) in each of the stages of the production process. A sample template to use in allocating direct and indirect costs for the collection in the laboratory stage is presented in Table 1 .
Second, once all costs in each of the six stages of production are accrued, the next step consists of distributing the total cost of the stages among the four cost objects previously identified: (1) stored product, (2) sample (3) reception of order and shipping and (4) order. The stages called collection in laboratory, processing of biospecimen and storage exclusively apply to the cost object identified as stored product. Table 2 presents the distribution of the costs to this cost object.
Once costs have been distributed to the cost object stored product, the next step is to calculate the cost per unit (see Table 2 ). To do this, it is necessary to estimate the number of product units stored per year, for example, DNA micro tubes or tissue cryomolds subsequently stored.
Then the costs of the stage sample processing are associated entirely to the cost object sample. Also, it is necessary to attach the corresponding proportional cost from the cost object stored product to this cost object. This amount is the   FIG. 3 . Schematic of the allocation, distribution and attachment of costs. For example, once the order is received, the next step is cutting the tissue stored to obtain the 50 samples the researcher requested. To calculate the cost of each sample, we should take into account two data sources. The first one is the cost of processing samples (fifth step ''sample processing'') and the other source is the number of stored tissues divided among the 100 samples we obtain from each stored product.
Finally, the total cost of the stages reception of order and distribution of samples are distributed to the cost object receipt of order and shipping. The scheme for this phase is presented in Table 3 .
Once the costs have been distributed and attached to cost objects sample and reception of order and shipping, the next step is to calculate the cost per unit (see Table 3 ). In the case of the sample, this amount is divided by the number of samples distributed per year. In the case of the cost object receipt of order and shipping, the number of orders received by the biobank annually is used to calculate the cost per unit. Finally, the cost estimate for each order is broken down as presented in Table 4 .
Therefore, the cost of an order is the result of the sum of the cost per unit of the sample times the number of samples required for that order, plus the cost per unit of reception of order and shipping.
Conclusions
Calculation and cost control tools have become instrumental in ensuring budget optimization. Biobanks are no exception to this trend. Moreover, they additionally target the reduction of costs associated with the management and storage of samples. Thus, some effort must be made in the areas of cost control and calculation. 9 The primary purpose of this article is to present the fundamentals of a cost calculation methodology for biobanks. The use of this methodology supplies information on the value of the biological material stored and provided to researchers as well as the cost of the reception and shipping activities. In addition, the proper use of this tool, among other things:
1. Allows for the analysis of the efficiency of the processes carried out within a biobank and the assessment of the economic viability of some collections of samples. 2. Provides the biobank managers with more professionalism when making a decision and fosters cooperation and mutual learning opportunities between different institutions. 3. Promotes the proper utilization of public resources and improves the budgeting process in the public sector. The stock of biological samples in storage is progressively and constantly on the rise. Yet there is a lack of space and resources to keep them under control and their maintenance costs are high. This makes the economic and technical management of biobanks a complicated task. Although the use of a cost accounting tool involves entering, storing and managing data sources throughout all the stages of the process, the proposed model can contribute to the efficient management of biological resources.
